Development and Validation of an Early Prediction Model for Severe Mycoplasma Pneumoniae Pneumonia in Children
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100050
- Beijing Friendship Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age between 1 month to 14 years
- diagnosed with Mycoplasma pneumoniae pneumonia
- hospital stay ≥ 72 hours
Exclusion Criteria:
- pulmonary chronicles
- cardiovascular conditions
- inherited metabolic disorders
- immuno-deficiency disorders
- coinfection with pathogens other than Mycoplasma pneumoniae
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Development
A primary cohort of eligible patients from the Beijing Friendship Hospital between 2018-1-1 and 2024-5-31 is used for model derivation.
|
medical history taking, blood test, pulmonary ultrasound are used for MPP and SMPP diagnosis
|
|
Internal cross-validation
A cohort of consecutive patients from the Beijing Friendship Hospital between 2018-1-1 and 2024-5-31 is used for internal cross-validation.
|
medical history taking, blood test, pulmonary ultrasound are used for MPP and SMPP diagnosis
|
|
External validation
A cohort of patients from the Beijing Friendship Hospital between 2024-6-1 and 2025-6-30 is used for internal cross-validation.
|
medical history taking, blood test, pulmonary ultrasound are used for MPP and SMPP diagnosis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area under the curve (AUC)
Time Frame: through the hospitalization, an average of 7 days
|
The AUC of prediction model for SMPP
|
through the hospitalization, an average of 7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity
Time Frame: through the hospitalization, an average of 7 days
|
The sensitivity of prediction model for SMPP
|
through the hospitalization, an average of 7 days
|
|
Specificity
Time Frame: through the hospitalization, an average of 7 days
|
Specificity of prediction model for SMPP
|
through the hospitalization, an average of 7 days
|
|
Positive prediction value (PPV)
Time Frame: through the hospitalization, an average of 7 days
|
Positive prediction value (PPV) of prediction model for SMPP
|
through the hospitalization, an average of 7 days
|
|
Negative prediction value (NPV)
Time Frame: through the hospitalization, an average of 7 days
|
Negative prediction value (NPV) of prediction model for SMPP
|
through the hospitalization, an average of 7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Infections
- Infections
- Respiratory Tract Diseases
- Lung Diseases
- Pneumonia
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Negative Bacterial Infections
- Pneumonia, Bacterial
- Mycoplasmatales Infections
- Mycoplasma Infections
- Pneumonia, Mycoplasma
- Investigative Techniques
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Hematologic Tests
Other Study ID Numbers
Other Study ID Numbers
- V120250926
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.